ADCs and DDR Inhibitors for Cancer Therapy Infographic
As DDRi and ADC combination therapies gain momentum, our team of experts have conducted the following analysis, using Beacon DDR data, to explore this promising approach. With its potential to deliver more targeted and tolerable treatments, understanding the synergy between DDR targets and ADC payloads is crucial to maximizing therapeutic success.
The infographic includes:
- An overview of the growth of ADC-DDRi clinical trials since the first trial initiation in 2015
- Analysis of DDR targets and payloads to help identify best combinations to maximize therapeutic benefit
- Insight into top biomarkers associated with combination trials
Learn More About ADC
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
